Savarese Gianluigi, Losco Teresa, Parente Antonio, Musella Francesca, Pirozzi Elisabetta, Mosca Susanna, Casaretti Laura, Formisano Roberto, Conte Sirio, Bologna Ada, Mattiello Giacomo, Perrone-Filardi Pasquale
Dipartimento di Medicina Interna, Universita degli Studi, Federico II, Napoli.
G Ital Cardiol (Rome). 2012 Feb;13(2):91-7. doi: 10.1714/1021.11141.
Heart failure is characterized by several abnormalities of sympathetic cardiac activity that can be assessed by 123I metaiodobenzylguanidine single photon emission computed tomography (MIBG SPECT). This technique may be useful in the clinical management of heart failure patients. Abnormal MIBG uptake has been demonstrated to be a predictor of death and arrhythmic events in heart failure patients with a prognostic power incremental to that of conventional risk markers; it may also be useful to identify patients at low risk of arrhythmias despite current guideline indications for an implantable cardioverter-defibrillator (ICD) or patients at high risk for arrhythmias not fulfilling ICD indications. This review will focus on the clinical applications of MIBG SPECT in chronic heart failure, on the basis of the most recent evidence.
心力衰竭的特征是交感神经心脏活动存在多种异常,可通过123I间碘苄胍单光子发射计算机断层扫描(MIBG SPECT)进行评估。这项技术可能对心力衰竭患者的临床管理有用。MIBG摄取异常已被证明是心力衰竭患者死亡和心律失常事件的预测指标,其预后能力优于传统风险标志物;它还可能有助于识别尽管目前有植入式心脏复律除颤器(ICD)指南指征但心律失常风险较低的患者,或未达到ICD指征但心律失常风险较高的患者。本综述将基于最新证据,重点探讨MIBG SPECT在慢性心力衰竭中的临床应用。